Human platelet response to three salicylate dosage forms

✍ Scribed by J. J. Thiessen; H. Grad; S. M. Macleod; M. Spino

• Publisher: John Wiley and Sons
• Year: 1983
• Tongue: English
• Weight: 419 KB
• Volume: 4
• Category: Article
• ISSN: 0142-2782
• DOI: 10.1002/bdd.2510040107

✦ Synopsis

Acetylsalicylic acid (ASA) inhibition of platelet aggregation as evaluated by collageninduced '4C-serotonin release, has been measured in 12 healthy male subjects. Each subject received a single oral dose (650mg) of enteric-coated ASA (ecASA) and compressed ASA tablets (cASA), or ecASA and sodium salicylate (578 mg) separated by a minimum of 5 weeks. The platelet response was related to plasma ASA and salicyclic acid determined by high-pressure liquid chromatography. Both ecASA and cASA inhibited I4C-serotonin release; no significant difference was observed in the maximum effect between these two products (p > 0.05). No relationship was found between the maximum observed plasma ASA level and the maximum effect. Further, no correlation was found between the maximum inhibition of L4C-serotonin release in vivo and the release predicted from in vitro experiments wherein the effect was measured after incubating plasma containing specified ASA concentrations.